Zydus Lifesciences Ltd. has completed its acquisition of U.S.-based Assertio Holdings in an all-cash transaction valued at $166.33 million, strengthening the company’s specialty pharmaceutical business in the United States.
Following the completion of the deal, Assertio will become a wholly owned subsidiary of Zydus and will be delisted from the Nasdaq Global Market.
The acquisition also adds a USFDA-approved biologics licence application (BLA) asset to Zydus’ oncology supportive care portfolio.
Transaction details
Zydus acquired all of Assertio’s common stock at $23.50 per share.
The total transaction value of $166.33 million includes shares and other equity instruments.
Key features of the deal include:
- Entirely cash-funded transaction
- No issuance of new equity
- No dilution for existing shareholders
- Full consideration placed with a paying agent for settlement
Shareholders who did not tender their shares in the initial offer will receive $23.50 per share in cash.
The transaction was carried out on an arm’s-length basis.
Rolvedon strengthens oncology portfolio
A key asset acquired through the transaction is Rolvedon, a cancer-support therapy approved by the U.S. Food and Drug Administration (USFDA).
The drug is used to reduce the risk of infections caused by weakened immunity during chemotherapy.
According to the company, the acquisition provides:
- An approved and market-ready product
- Entry into the oncology supportive care segment
- Access to a business with limited competition
- Exposure to a high-value specialty market
Strategic significance
The deal gives Zydus access to an established commercial platform in the U.S. specialty pharma market.
Assertio’s oncology portfolio and the revenue generated by Rolvedon are expected to support the expansion.
The lead product generated revenue of about $68 million.
The acquisition is also expected to support Zydus’ shift toward higher-margin specialty therapies and reduce reliance on traditional generics.
Stock and valuation
Zydus Lifesciences was trading around Rs. 1,070.
The stock opened at Rs. 1,069.90, touched an intraday high of Rs. 1,077.80, and fell to a low of Rs. 1,065.
The company had a market capitalization of Rs. 1,07,622 crore.
Its price-to-earnings ratio stood at 19.8 times, compared with the peer median of 32.61 times.
Financial performance
For Q4 FY26, Zydus reported:
- Revenue from operations of Rs. 7,587 crore
- Revenue of Rs. 6,864 crore in Q3 FY26
- Revenue of Rs. 6,528 crore in Q4 FY25
This represented:
- Quarter-on-quarter growth of 10.53 percent
- Year-on-year growth of 16.22 percent
Net profit for Q4 FY26 stood at Rs. 1,341 crore, compared with:
- Rs. 1,023 crore in Q3 FY26
- Rs. 1,244 crore in Q4 FY25
Profit increased:
- 31.08 percent sequentially
- 7.79 percent year-on-year
Earnings per share rose to Rs. 12.65 from Rs. 10.36 in the previous quarter.
About the company
Zydus Lifesciences has operations across generics, vaccines, biologics and specialty medicines and maintains a significant presence in the U.S. market.
The company has been expanding its focus toward innovation-led and specialty-driven businesses.
TL;DR:
Zydus Lifesciences has completed the $166.33 million acquisition of Assertio Holdings. The deal brings cancer-support drug Rolvedon into its portfolio and gives the company a ready-made platform to expand its specialty pharma business in the U.S.
AI summary:
- Zydus completed the acquisition of Assertio Holdings for $166.33 million.
- The transaction was entirely cash-funded with no equity dilution.
- Assertio will become a wholly owned subsidiary and be delisted from Nasdaq.
- The deal adds USFDA-approved cancer-support drug Rolvedon.
- Q4 FY26 net profit rose 31.08% sequentially to Rs. 1,341 crore.
